REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. decreased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 31.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 559,872 shares of the biotechnology company's stock after selling 256,512 shares during the period. Assenagon Asset Management S.A. owned about 1.13% of REGENXBIO worth $5,873,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in RGNX. Vanguard Group Inc. lifted its holdings in shares of REGENXBIO by 9.8% during the 1st quarter. Vanguard Group Inc. now owns 4,876,881 shares of the biotechnology company's stock valued at $102,756,000 after buying an additional 436,043 shares during the period. Redmile Group LLC raised its position in shares of REGENXBIO by 21.0% during the 1st quarter. Redmile Group LLC now owns 4,551,556 shares of the biotechnology company's stock valued at $95,901,000 after buying an additional 790,866 shares in the last quarter. Integral Health Asset Management LLC raised its position in REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company's stock valued at $11,115,000 after purchasing an additional 190,000 shares during the period. Bank of New York Mellon Corp increased its position in REGENXBIO by 9.3% during the second quarter. Bank of New York Mellon Corp now owns 339,514 shares of the biotechnology company's stock valued at $3,972,000 after acquiring an additional 28,846 shares during the last quarter. Finally, Millennium Management LLC increased its position in REGENXBIO by 84.8% during the second quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company's stock valued at $3,586,000 after acquiring an additional 140,666 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company's stock.

REGENXBIO Trading Down 1.3 %

Shares of NASDAQ RGNX traded down $0.12 during trading hours on Wednesday, reaching $8.94. The stock had a trading volume of 195,044 shares, compared to its average volume of 592,698. The firm has a market cap of $440.35 million, a price-to-earnings ratio of -1.54 and a beta of 1.21. REGENXBIO Inc. has a fifty-two week low of $8.90 and a fifty-two week high of $28.80. The firm has a 50-day moving average of $10.98 and a 200-day moving average of $12.84.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The firm had revenue of $22.30 million during the quarter, compared to analysts' expectations of $22.97 million. During the same period in the prior year, the firm earned ($1.66) EPS. The business's revenue was up 11.6% on a year-over-year basis. On average, equities analysts predict that REGENXBIO Inc. will post -4.66 EPS for the current year.

Analyst Upgrades and Downgrades

RGNX has been the subject of a number of recent analyst reports. Raymond James reissued an "outperform" rating and set a $18.00 target price on shares of REGENXBIO in a research note on Thursday, October 10th. Barclays decreased their price target on shares of REGENXBIO from $55.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, August 5th. Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Tuesday, October 22nd. StockNews.com upgraded shares of REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday, September 20th. Finally, HC Wainwright restated a "buy" rating and issued a $39.00 price objective on shares of REGENXBIO in a research report on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, REGENXBIO has a consensus rating of "Moderate Buy" and a consensus target price of $35.45.

Insiders Place Their Bets

In other news, Director Argeris N. Karabelas sold 10,100 shares of the firm's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $13.51, for a total value of $136,451.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company's stock, valued at $152,473.86. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Argeris N. Karabelas sold 10,100 shares of the firm's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $13.51, for a total value of $136,451.00. Following the completion of the sale, the director now directly owns 11,286 shares of the company's stock, valued at $152,473.86. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Argeris N. Karabelas sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total value of $101,100.00. Following the completion of the transaction, the director now directly owns 11,286 shares of the company's stock, valued at $114,101.46. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,200 shares of company stock valued at $354,651. 13.13% of the stock is owned by company insiders.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.